Omega Fund Management has significantly increased its stake in Bicara Therapeutics, acquiring 187,500 shares for an estimated $3.23 million. As of March 31, 2026, this investment accounts for 29.16% of Omega’s reportable assets, reflecting strong confidence in Bicara’s lead oncology therapy, ficerafusp alfa, particularly after the stock has surged nearly 50% over the past year. Bicara continues to advance its clinical trials and, despite incurring wider quarterly losses, has a solid financial position with $539.8 million in cash to fund operations into 2029. The upcoming performance of its therapies will be crucial for long-term investors in the competitive biotech landscape.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/coverage/filings/2026/05/15/bicara-stock-is-up-50-and-one-biotech-investor-has-made-it-a-29-portfolio-bet/
